NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursday, June 30, 2022, before market open. The Company will host a corresponding conference call and
RNS Number : 8594P Renalytix PLC 23 June 2022 Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30 NEW YORK and SALT LAKE CITY , June 23, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022
Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outcomes, alleviate patient suffering, and reduce significant financial burden associated with rapidly
RNS Number : 4139O Renalytix PLC 10 June 2022 Renalytix plc ("Renalytix" or the "Company") 1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX TM Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease Patients Late-breaking data presented at American
NEW YORK and SALT LAKE CITY, June 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth Stock Conference on Thursday, June 9 at 2:00 p.m. CT. Interested parties may access a live and archived webcast
RNS Number : 0740O Renalytix PLC 08 June 2022 Renalytix to Present at 42 nd Annual William Blair Growth Stock Conference NEW YORK and SALT LAKE CITY , June 8, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth
Data shared in oral presentation at American Diabetes Association 82 nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cause of death in patients with diabetes and chronic kidney disease NEW YORK and SALT LAKE CITY,
RNS Number : 6870N Renalytix PLC 06 June 2022 Renalytix plc ("Renalytix" or the "Company") Renalytix held Two Data Presentations on KidneyIntelX at American Diabetes Association 82 nd Scientific Sessions® Real-world clinical utility in 1,112 patients tested with KidneyIntelX KidneyIntelX
RNS Number : 6872N Renalytix PLC 06 June 2022 Renalytix plc ("Renalytix" or the "Company") KidneyIntelX TM Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort Data shared in oral presentation at American
Real-world clinical utility in 1,112 patients tested with KidneyIntelX KidneyIntelX stratification for cardiovascular risk in 1,278 diabetic kidney disease patients NEW YORK and SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced its